Evolving chemotherapeutics

Posts in category Presentations

ASCO 2017 – Detailed clinical t...

ASCO 2017 – Detailed clinical trial results presented

The phase 1 trial results were presented in greater detail in two posters at ASCO 2017 in Chicago this week. Professor Phil Clingan presented a poster: Deflexifol (a novel formulation of 5FU) Phase 1 Dose Escalation Study of Infusional or Bolus Schedules After Failure of Standard Treatment Clingan P. et al J Clin Oncol 35, 2017 […]

Deflexifol is safer for patients

Deflexifol is safer for patients

Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles. Click to read this article.

Potent, with fewer side effects

Potent, with fewer side effects

Deflexifol (formerly Fluorodex) maintains in-vitro potency, overcomes incompatibility of 5-fluorouracil and folinic acid and may reduce phlebitis, catheter blockages and thromboembolic events. Development and assessment of novel all-in-one parenteral formulations with integrated anticoagulant properties for the concomitant delivery of 5-fluorouracil and calcium folinate. Read our article signalling improved patient outcomes from Deflexifol.

New hope for patients

New hope for patients

New hope being offered by Deflexifol to chemotherapy patients. Read here about new hope for chemotherapy patients.

New way to use an older drug

New way to use an older drug

Deflexifol is a new way of using an older drug. Read more.